PureTech Health (LON:PRTC) Trading 6.3% Higher – Time to Buy?

PureTech Health plc (LON:PRTC)’s share price traded up 6.3% during mid-day trading on Monday . The company traded as high as GBX 127 ($1.67) and last traded at GBX 125.40 ($1.65). 1,234,305 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 1,059,029 shares. The stock had previously closed at GBX 118 ($1.56).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 455 ($6.00) target price on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Stock Performance

The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The company has a market capitalization of £376.68 million, a PE ratio of -5.14 and a beta of 1.02. The business has a 50 day simple moving average of GBX 134.79 and a 200 day simple moving average of GBX 147.92.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.